Safety and efficacy of second-generation drug-eluting stents compared with bare-metal stents: An updated meta-analysis and regression of 9 randomized clinical trials

Ahmed N. Mahmoud, Nikhil H. Shah, Islam Y. Elgendy, Nayan Agarwal, Akram Y. Elgendy, Amgad Mentias, Amr F. Barakat, Dhruv Mahtta, R. David Anderson, Anthony A. Bavry

Research output: Contribution to journalReview article

5 Scopus citations

Abstract

The efficacy of second-generation drug-eluting stents (DES; eg, everolimus and zotarolimus) compared with bare-metal stents (BMS) in patients undergoing percutaneous coronary intervention was challenged recently by new evidence from large clinical trials. Thus, we aimed to conduct an updated systematic review and meta-analysis of randomized clinical trials (RCTs) evaluating the efficacy and safety of second-generation DES compared with BMS. Electronic databases were systematically searched for all RCTs comparing second-generation DES with BMS and reporting clinical outcomes. The primary efficacy outcome was major adverse cardiac events (MACE); the primary safety outcome was definite stent thrombosis. The DerSimonian and Laird method was used for estimation of summary risk ratios (RR). A total of 9 trials involving 17 682 patients were included in the final analysis. Compared with BMS, second-generation DES were associated with decreased incidence of MACE (RR: 0.78, 95% confidence interval [CI]: 0.69-0.88), driven by the decreased incidence of myocardial infarction (MI) (RR: 0.67, 95% CI: 0.48-0.95), target-lesion revascularization (RR: 0.47, 95% CI: 0.42-0.53), definite stent thrombosis (RR: 0.57, 95% CI: 0.41-0.78), and definite/probable stent thrombosis (RR: 0.54, 95% CI: 0.38-0.80). The incidence of all-cause mortality was similar between groups (RR: 0.94, 95% CI: 0.79-1.10). Meta-regression showed lower incidences of MI with DES implantation in elderly and diabetic patients (P = 0.026 and P < 0.0001, respectively). Compared with BMS, second-generation DES appear to be associated with a lower incidence of MACE, mainly driven by lower rates of target-lesion revascularization, MI, and stent thrombosis. However, all-cause mortality appears similar between groups.

Original languageEnglish (US)
Pages (from-to)151-158
Number of pages8
JournalClinical Cardiology
Volume41
Issue number1
DOIs
StatePublished - Jan 2018
Externally publishedYes

Keywords

  • Coronary Artery Disease
  • Drug-Eluting Stents
  • Percutaneous Coronary Intervention

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Safety and efficacy of second-generation drug-eluting stents compared with bare-metal stents: An updated meta-analysis and regression of 9 randomized clinical trials'. Together they form a unique fingerprint.

  • Cite this

    Mahmoud, A. N., Shah, N. H., Elgendy, I. Y., Agarwal, N., Elgendy, A. Y., Mentias, A., Barakat, A. F., Mahtta, D., David Anderson, R., & Bavry, A. A. (2018). Safety and efficacy of second-generation drug-eluting stents compared with bare-metal stents: An updated meta-analysis and regression of 9 randomized clinical trials. Clinical Cardiology, 41(1), 151-158. https://doi.org/10.1002/clc.22855